PEG-sTNF-RI. Amgen.
PEGylated soluble tumor necrosis factor-receptor type I (PEG-sTNF-RI) is a second-generation TNF-binding protein in development by Amgen as a potential treatment for rheumatoid arthritis (RA). PEG-sTNF-RI is an optimized, monomeric form of the first-generation molecule, TNFbp. By 1999, PEG-sTNF-RI was undergoing phase II trials for RA, and these trials were ongoing in March 2003.
Darlington
Cynthia
C
Department of Pharmacology and Toxicology, School of Medical Sciences, University of Otago, Dunedin, New Zealand. cynthia.darlington@stonebow.otago.ac.nz
D000818:Animals; D015703:Antigens, CD / Q000494:pharmacology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D047888:Receptors, Tumor Necrosis Factor, Type I; D013678:Technology, Pharmaceutical / Q000379:methods*
D015703:Antigens, CD; D018501:Antirheumatic Agents; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D011092:Polyethylene Glycols